BioArctic Q2 FY26 turns to net loss of SEK 11.2 million; revenue falls to SEK 247.5 million
LLY•Q2 FY26 results turn to loss
- BioArctic swung to an operating loss of SEK 6.5 million in April–June 2026 as net revenues fell to SEK 247.5 million.
- Profit for the period turned to a loss of SEK 11.2 million; earnings per share were SEK -0.13.
- Royalty income from Leqembi rose to SEK 179.4 million; global Leqembi sales climbed to JPY 29.3 billion.
- Eisai forecast fiscal 2026 Leqembi sales of JPY 143.5 billion, implying 63% growth versus the prior year.
BrainTransporter collaboration with Eli Lilly
- BioArctic signed a BrainTransporter collaboration with Eli Lilly, including a USD 30 million upfront and up to USD 800 million milestones.
